PLGA-PEG NPs coupled with a paclitaxel-loaded CD133 aptamer (N-Pac-CD133) were designed to eliminate lung cancer stem cells, and the results showed that N-Pac-CD133 had significantly enhanced targeting and efficacy against lung cancer stem cells [168]. The gene discussed is PROM1; the disease is lung carcinoma.